Rebecca Taub sold $10M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 29,101 shares at an average of $353.19, traded Jul 16, 2025, filed Jul 18, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.3M at market
- 0Share of holdings soldSold 6.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-035340, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2025 | MOption exercise Common Stock10b5-1 | +26,444 | $9.45 | $250k | 487,488 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -6,000 | $350.19 | $2.1M | 481,488 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -1,897 | $351.37 | $667k | 479,591 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -2,357 | $352.64 | $831k | 477,234 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -2,569 | $353.82 | $909k | 474,665 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -5,800 | $354.61 | $2.1M | 468,865 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -6,441 | $355.61 | $2.3M | 462,424 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -1,380 | $356.52 | $492k | 461,044 | Jul 18, 2025 |
| Jul 17, 2025 | MOption exercise Common Stock10b5-1 | +2,657 | $9.45 | $25k | 463,701 | Jul 18, 2025 |
| Jul 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,057 | $350.09 | $720k | 461,644 | Jul 18, 2025 |
| Jul 17, 2025 | SOpen-market sale Common Stock10b5-1 | -600 | $351.50 | $211k | 461,044 | Jul 18, 2025 |
| Jul 16, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -26,444 | $0.00 | $0 | 50,120 | Jul 18, 2025 |
| Jul 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,657 | $0.00 | $0 | 47,463 | Jul 18, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $505k 1,183 shares | -11% | |
| 27Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $449k 910 shares | -9% | |
| 44Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $319k 647 shares | -0% | |
| 62Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $777k 1,577 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.